摘要
Prostate cancer (PCa) is one of the most commonly diagnosed cancers in men globally and is primarily driven by the androgen receptor (AR). Current therapeutic options for patients with metastatic disease include androgen deprivation therapy (ADT) such as enzalutamide. Despite an initial response to ADT, over half of patients receiving this treatment eventually progress to a treatment-resistant form of PCa, known as castration resistant PCa (CRPC). CRPC is currently incurable, although therapeutics are given to manage symptoms of the disease. N6-methyladenosine (m6A) is the most prevalent internal chemical modification in all eukaryotic cells and plays a role in a dynamic range of biological processes, including transcriptional and translational regulation, cell cycle progression and metabolism. Aberrant m6A has been associated with PCa. The addition of m6A is catalysed by “writers” such as METTL3, METTL14 complex and METTL16. The m6A methylation marks are removed by demethylases, also known as “erasers” (FTO and ALKBH5), and interpreted and processed by “readers” such as YTHDC and other YTH family members. While the METTL3:METTL14 RNA methyltransferase complex targets mRNA, the METTL16 methyltransferase has a more limited substrate preference for a select number of RNAs, including U6 snRNA, MAT2A RNA and MALAT1 lncRNA, which has also been implicated in PCa. Although METTL16 has been associated with several cancer types, its role appears to be context-dependent, and its clinical and functional significance in PCa remains poorly understood. The wealth of evidence supporting the clinical and mechanistic relevance of m6A in PCa progression and treatment resistance, supports the hypothesis that METTL16 plays an important role in pro-oncogenic signalling in PCa. To test this hypothesis, this study aimed to quantify METTL16 expression in non-malignant and primary PCa tissue patient specimens and investigate its association with clinical and pathological parameters. Additionally, the functional role of METTL16 in enzalutamide-sensitive and resistant cell lines was assessed by siRNA-mediated METTL16 Knockdown and analysis of differentially expressed genes and alternative splicing events were performed using RNA sequencing data. A positive correlation was observed between nuclear METTL16 and METTL3 expression in PCa specimens. Increased METTL16 nuclear expression was associated with more favourable disease outcomes, such as reduced extra prostatic extension and recurrence. In contrast, increased METTL16 cytoplasmic expression was associated with less favourable outcomes, including a higher Gleason score, perineural invasion and extra prostatic extension. SiRNA-mediated METTL16 depletion was achieved at the protein and mRNA level in both enzalutamide-sensitive and resistant cell lines (C4-2 and C4-2enzR, respectively). METTL3 mRNA levels were significantly downregulated following METT16 depletion in C4-2enzR but not C4-2, suggesting a possible mechanistic link between the two methyltransferases in an enzalutamide-resistant environment. Although C4-2 RNA-seq data showed no statistically significant enriched pathways, C4- 2enzR had substantially more. Oxidative phosphorylation was one of the significantly enriched downregulated pathways, while ribosome and spliceosome were among the significantly upregulated pathways. Splicing analysis also displayed more significant enrichments in splicing events in C4-2enzR, compared to C4-2. KEGG pathways with significantly enriched splicing events in C4-2enzR included mTOR, Wnt signalling and DNA repair mechanisms. Together, this study suggests that METTL16 is associated with positive or negative prognostic indicators, depending on cellular localisation, highlighting a complex, context specific role that METTL16 plays in PCa. Additionally, this study highlights a more prominent role of METTL16 in enzalutamide-resistant PCa cells compared to enzalutamide-sensitive cells. These findings also demonstrate a previously unknown potential mechanistic link between METTL16 and METTL3, which was not observed in the enzalutamide-sensitive cells. Collectively, these findings contribute to a deeper understanding of the mechanisms that drive ADT resistance in prostate cancer.